Cytochrome P450 enzyme mediated herbal drug interactions (part 1)

EXCLI Journal

Volumn 13, Issue , 2014, Pages 347-391

  Wanwimolruk, Sompon ^a   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Botanical supplements; CYP; Dietary supplements; Drug interactions; Herbal drug interactions; Herbal medicines

Indexed keywords

ALPRAZOLAM; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; CONTRACEPTIVE AGENT; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DIAZEPAM; ECHINACEA EXTRACT; FLURBIPROFEN; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; HYDRASTIS EXTRACT; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; METHADONE; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PARACETAMOL; PLANT EXTRACT; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; ECHINACEA; ENZYME ACTIVITY; GARLIC; GINKGO BILOBA; HERB DRUG INTERACTION; HUMAN; HYDRASTIS; IN VITRO STUDY; IN VIVO STUDY; PHYTOCHEMISTRY; PLANT LEAF; PLANT ROOT; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; SILYBUM MARIANUM; XENOBIOTIC METABOLISM;

EID: 84899136682     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (210)

1. Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS et al. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 2010;69:508-15.
2. Abernethy DR, Kaminsky LS, Dickinson TH. Selec-tive inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 1991;257:411-5.
3. An G, Morris ME. Herbal supplement-based interac-tions. In: Pang KS, Rodrigues AD, Peter RM (eds): Enzyme-and transporter-based drug-drug interac-tions (pp 555-84). New York: Springer, 2010.
4. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ et al. Association of Alzhei-mer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003, 58:372-7.
5. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-16.
6. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med 2005;71:331-7.
7. Badal S, Gallimore W, Huang G, Tzeng TR, Delgo-da R. Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata. Org Med Chem Lett 2012;11:21-8.
8. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine interac-tion: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468-77.
9. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. 1998. Br J Clin Pharmacol 2004;58:S831-40; discussion S841-3.
10. Bailey DG, Dresser GK, Leake BF, Kim KB. Nar-ingin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (oatp 1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81:495-502.
11. Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ 2013;185:309-16.
12. Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen phar-macokinetics. Ann Pharmacother 2007;4:229-34.
13. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of re-polarization on the electrocardiogram. Clin Pharma-col Ther 1996;59:383-8.
14. Berginc K, Kristl A. The effect of garlic supple-ments and phytochemicals on the ADMET proper-ties of drugs. Expert Opin Drug Metab Toxicol 2012;8:295-310.
15. Berginc K, Milisav I, Kristl A. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet 2010;25:521-30.
16. Bolley R, Zülke C, Kammerl M, Fischereder M, Krämer BK. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St. John's wort. Transplantation 2002;73:1009.
17. Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res 2008;52:764-71.
18. Borrelli F, Capasso R, Izzo AA. Garlic (Allium sa-tivum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res 2007;51:1386-97.
19. Brady JF, Li DC, Ishizahi H, Yang CS. Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities. Cancer Res 1988;48:5937-40.
20. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum maria-num) inhibit CYP2C9-mediated warfarin metabo-lism at clinically achievable concentrations. J Phar-macol Exp Ther 2010;332:1081-7.
21. Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003;10:163-9.
22. Brevoort P. The booming U.S. botanical market: A new overview. Herbalgram 1998;44:33-48.
23. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cyto-chrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commer-cial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007;85:966-78.
24. Burstein AH, Horton RL, Dunn T, Alfaro RM, Pis-citelli SC, Theodore W. Lack of effect of St. John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-12.
25. Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy. A quick reference to Cavaliere C, Rea P, Blumenthal M. Herbal supplement sales in the United States show growth in all channels. Herbal-gram 2008;78:60-3.
26. Cerella C, Dicato M, Jacob C, Diederich M. Chemi-cal properties and mechanisms determining the anti-cancer action of garlic-derived organic sulfur com-pounds. Anticancer Agents Med Chem 2011;11:267-71.
27. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103-12.
28. Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cyto-chrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62: 135-142.
29. Chandra-Kuntal K, Lee J, Singh SV. Critical role for reactive oxygen species in apoptosis induction and cell migration inhibition by diallyl trisulfide, a can-cer chemopreventive component of garlic. Breast Cancer Res Treat 2013;138:69-79.
30. Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk as-sessment. Pharmacol Res 2010;62:207-27.
31. Cott JM. Herb-drug interactions: theory versus prac-tice. Mol Nutr Food Res 2008;52:745-6.
32. Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-40.
33. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R et al. Coadministration of milk this-tle and indinavir in healthy subjects. Pharmacothera-py 2003;23:866-70.
34. Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially avail-able St. John's wort preparations. Can J Clin Phar-macol 2003;10:114-8.
35. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
36. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G et al. Oral administration of a low dose of midazolam (75 microg) as an in vivoprobe for CYP3A activity. Eur J Clin Pharmacol 2004;60:237-46.
37. Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's Wort-a case report. Pharmacopsychiatry 2003;36:35-7.
38. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M et al. Trends in alterna-tive medicine use in the United States, 1990-1997: Results of a follow-up national study. JAMA 1998; 280:1569-75.
39. Ernst E, Pittler MH, Wider B. The desktop guide to complementary and alternative medicine. An evi-dence-based approach. Philadelphia, PA: Mosby Elsevier, 2006.
40. Ernst E, Pittler MH, Wider B, Boddy K. Oxford handbook of complementary medicine. Oxford: Ox-ford University Press, 2008.
41. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhi-bition and P-glycoprotein interaction with golden-seal, Ginkgo bloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007;73:731-41.
42. Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB. Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. Planta Med 2011;77:835-40.
43. European Medicines Agency (EMA). Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev. 1; Corr.; 22 April 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf; Accessed May 01, 2013.
44. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Cright-on F, Harrison GS et al. A phase I and pharmacoki-netic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-46.
45. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT et al. An in vitro evalua-tion of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001;4:176-84.
46. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 2005;45:203-96.
47. rded. (pp 279-89). London: Pharmaceutical Press, 2007.
48. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-95.
49. Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007;73:1429-35.
50. Fukao T, Hosono T, Misawa S, Seki T, Ariga T. The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride. Food Chem Toxicol 2004;42:743-9.
51. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volun-teers. Br J Clin Pharmacol 2003;55:199-202.
52. Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induc-tion of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch Pharmacol 2007;375:377-82.
53. Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interac-tions in cancer patients. Cancer Treat Rev 2013;39: 773-83.
54. Gonzalez FJ. Human cytochromes P450: problems and prospects. TiPS 1992;131:346-52.
55. Gonzalez FJ, Gelboin HV. Role of human cyto-chromes P450 in the metabolic activation of chemi-cal carcinogens and toxins. Drug Metabol Rev 1994; 26:165-83.
56. Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hol-lenberg PF et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposi-tion in humans. Clin Pharmacol Ther 2004;76:607-17.
57. Gorski JC, Huang SM, Pinto A, Hamman MA, Hil-ligoss JK, Zaheer NA et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004;75:89-100.
58. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ et al. Time course of recovery of cytochrome p450 3A function after sin-gle doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121-9.
59. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006a;46:214-21.
60. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr 2006b:136:806S-809S.
61. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
62. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-407.
63. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cyto-chromes P450 in humans. Eur J Clin Pharmacol 2012;68:213-7.
64. Gurley BJ, Hagan DW. Herbal and dietary supple-ment interactions with drugs. In: McCabe BJ, Frankel EH, Wolfe JJ (eds): Handbook of food-drug interactions /(pp 259-93). Boca Raton: CRC Press, 2003.
65. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Cytochrome P450 pheno-typic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87.
66. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J et al. in vivoassessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea pur-purea, milk thistle, and saw palmetto. Clin Pharma-col Ther 2004;76:428-40.
67. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Clinical assessment of ef-fects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, gar-lic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005a;22:525-39.
68. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. in vivoeffects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005b;77:415-26.
69. Gurley BJ, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006;46:201-13.
70. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava ka-va (Piper methysticum), inhibits human CYP3A ac-tivity in vivo. Clin Pharmacol Ther 2008a;83:61-9.
71. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in hu-mans: effects of milk thistle, black cohosh, golden-seal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008b;52:755-63.
72. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 2012;78:1490-514.
73. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW et al. The effect of gar-lic extract on human metabolism of acetaminophen. Cancer Res 1994;3:155-60.
74. Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G: Effect of simultaneous induction and inhibition of CYP3A by St. John's Wort and ritonavir on CYP3A activity. Clin Phar-macol Ther 2010;87:191-6.
75. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ et al. The interaction be-tween St. John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74:525-35.
76. Haller CA, Duan M, Benowitz NL, Jocob P 3rd. Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. J Anal Toxicol 2004;28:145-51.
77. Han Y, Guo D, Chen YY, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese vol-unteers. Eur J Clin Pharmacol 2009;65:585-91.
78. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78:1458-77.
79. Ho BE, Shen DD, McCune JS, Bui T, Risler L, Yang Z et al. Effects of garlic on cytochromes P450 2C9-and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 2010;78:473-81.
80. Ho P-C, Ghose K, Saville DJ, Wanwimolruk S. Ef-fect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 2000;56: 693-8.
81. Ho P-C, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharmaceut Sci 2001;4:217-27.
82. Ihl R. Gingko biloba extract EGb 761®: clinical data in dementia. Int Psychogeriatr 2012;24(Suppl 1): S35-40.
83. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S et al. The recovery time-course of CYP3A after induction by St. John's wort admin-istration. Br J Clin Pharmacol 2008;65:701-7.
84. Ioannides C. Effect of diet and nutrition on the ex-pression of cytochromes P450. Xenobiotica 1999; 29:109-54.
85. Izzo AA. Interactions between herbs and conven-tional drugs: overview of the clinical data. Med Princ Pract 2012;21:404-28.
86. Izzo AA, Ernst E. Interactions between herbal medi-cines and prescribed drugs: A systematic review. Drugs 2001;61:2163-75.
87. Izzo AA, Ernst E. Interactions between herbal medi-cines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777-98.
88. Jacek H, Rentsch KM, Steinert HC, Pauli-Magnus C, Meier PJ, Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test. Clin Pharmacol Ther 2004;75:P80.
89. Jann MW, Shirley KL, Small GW. Clinical pharma-cokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39.
90. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC et al. Effect of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9.
91. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacody-namics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-32.
92. Johne A, Roots I. Clinical drug interactions with medicinal herbs. Evid Based Integr Med 2005;2: 207-28.
93. Kennedy DO, Wightman EL. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr 2011;2:32-50.
94. Kennedy J, Wang CC, Wu CH. Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat Med 2008;5: 451-6.
95. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS et al. Induction and inhibition of cyto-chromes P450 by the St. John's wort constituent hyperforin in human he-patocyte cultures. Drug Metab Dispos 2004;32:512-8.
96. Kressmann S, Müller WE, Blume HH. Pharmaceuti-cal quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002;54:661-9.
97. Lam YWF, Ernst E. Botanical products-drug inter-actions: focus on garlic, ginkgo and ginseng. In: Lam YWF, Huang SM, Hall SD (eds): Herbal sup-plements-drug interactions, Vol. 162 (pp 107-21). London: Taylor & Francis, 2006.
98. Leber HW, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittel-forschung 1976;26:1603-5.
99. Lee CG, Gottesman MM, Cardarelli CO, Rama-chandra M, Jeang KT, Ambudkar SV et al. HIV-1 protease inhibitors are substrates for the MDR1 mul-tidrug trans-porter. Biochemistry 1998;37:3594-601.
100. Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL et al. Effects of Ginkgo biloba extract on the pharmacoki-netics of bupropion in healthy volunteers. Br J Clin Pharmacol 2009a;68:201-6.
101. Lei HP, Wang G, Wang LS, Ou-yang DS, Chen H, Li Q et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volun-teers identified as CYP2C19 poor and extensive me-tabolizers. Ann Pharmacother 2009b;43:726-31.
102. Lightfoot TJ, Coxhead JM, Cupid BC, Nicholson S, Garner RC et al. Analysis of DNA adducts by accel-erator mass spectrometry in human breast tissue af-ter administration of 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine and benzy[a]pyrene. Mutat Res 2000;472:119-27.
103. Lin HL, Kenaan C, Hollenberg PF. Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermedi-ate that contri-butes to the grapefruit juice effect. Drug Metab Dispos 2012;40:998-1006.
104. Linde K, Berner MM, Kriston L. St. John's wort for major depression. Cochrane Database Syst Rev 2008;(4)CD000448.
105. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroen-terol 2011;17 2288-301.
106. Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 2001;20:321-327.
107. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA et al. Grapefruit juice in-creases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
108. Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006;136(Suppl3):793S-5S.
109. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B et al. Hyperforin content determines the magnitude of the St. John's wort-cyclosporine A drug interaction. Clin Pharmacol Ther 2004;76:330-40.
110. Maliakal P, Umesh T, Sankpal, Riyaz Basha, Maliakal C, Ledford A, Wanwimolruk S. Relevance of drug metabolizing enzyme activity modulation by tea polyphenols in the inhibition of esophageal tu-morigenesis. Med Chem 2011;7:480-7.
111. Mandlekar S, Hong JL, Kong AN. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr Drug Metab 2006;7:661-75.
112. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66: PL133-9.
113. Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharma-col 2003a;23:576-81.
114. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS et al. Effect of St. John's wort on drug metabolism by induction of cyto-chrome P450 3A4 enzyme, JAMA 2003b;290;1500-4.
115. Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sa-tivum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Phar-macol Ther 2003c;74:170-7.
116. Markovitz JS, von Moltke LL, Donovan JL. Predict-ing interactions between conventional medications and botanical products on the basisof in vitro inves-tigations. Mol Nutr Food Res 2008; 52:747-54.
117. Miller LG. Drug interactions known or potentially associated with St. John's Wort. J Herb Pharmaco-ther 2001;1:51-64.
118. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS et al. Pharmaco-dynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008; 154:1691-700.
119. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006;13: 24-31.
120. Moltó J, Valle M, Miranda C, Cedeño S, Negredo E, Barbanoj MJ et al. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011;55:326-30.
121. Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 Induction. Drug Metab Dispos 2013;41:1494-504.
122. Moore LB, Goodwin B, Jones SA, Wisely WB, Serabjit-Singh CJ, Willson TM et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000;97:7500-2.
123. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volun-teers. J Clin Pharmacol 2004;44:95-101.
124. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006;62:29-36.
125. Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H et al. No clin-ically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volun-teers. Eur J Clin Pharmacol 2009;65:81-7.
126. Murphy PA. St. John's wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002;47:447-50.
127. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's wort with oral contra-ceptives: effects on the pharmacokinetics of nore-thindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402-8.
128. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab 2006;7:67-81.
129. Nafziger AN, Bertino JS Jr. Low hepatic cyto-chrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther 2007; 82:379.
130. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Poten-tial metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502.
131. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991;247:267-81.
132. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62.
133. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
134. Niestroy J, Barbara A, Herbst K, Rode S, van Liempt M, Roos PH. Single and concerted effects of benzo[a]pyrene and flavonoids on the Ahr and Nrf2-pathway in the human colon carcinoma cell line Ca-co-2. Toxicol in Vitro 2012;25:671-683.
135. Olesen C, Harbig P, Barat I, Damsgaard EM. Ab-sence of 'over-the-counter' medicinal products in on-line prescription records: a risk factor of over-looking interactions in the elderly. Pharmacoepi-demiol Drug Safety 2013; 22:145-50.
136. Paine MF, Criss AB, Watkins PB. Two major grape-fruit juice components differ in time to onset of in-testinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005;312:1151-60.
137. Pathak A, Léger P, Bagheri H, Senard JM, Boccalon H, Montastruc JL. Garlic interaction with fluindione: a case report. Therapie 2003;58:380-1.
138. Patten CJ, Smith TJ, Friesen MJ, Tynes RE, Yang CS, Murphy SE et al. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitroso-nornicotine alpha-hydroxylation by human liver mi-crosomes. Carcinogenesis 1997;18:1623-30.
139. Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey Jr RT. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharma-col 2008;48:671-80.
140. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010;30:797-805.
141. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56:683-90.
142. Philp RB. Herbal-drug interactions and adverse ef-fects: an evidence-based quick reference guide (pp 1-10). New York: McGraw-Hill, 2004.
143. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW et al. A randomized trial of the effect of plant-based dietary pattern on additional breast can-cer events and survival: the Women's Healthy Eat-ing and Living (WHEL) study. Control Clin Trials 2002;23:728-56.
144. Pierre SV, Lesnik P, Moreau M, Bonello L, Droy-Lefaix MT, Sennoune S et al. The standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipo-proteins. Cell Mol Biol 2008;54(Suppl):OL1032-42.
145. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-8.
146. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Fallon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002a;34:234-8.
147. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. 2002b;22:551-6.
148. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clini-cal medicine. Indian J Med Res 2006;124:491-504.
149. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreat-ment on metabolism and disposition of metronida-zole. Arzneimittelforschung 2004;54:109-13.
150. Rao BN, Srinivas M, Kumar YS, Rao YM. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metab Drug Inter-act 2007;22:175-85.
151. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T et al. Hydroxylation of warfa-rin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
152. Richardson MA, Ramirez T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medi-cine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18: 2505-14.
153. Robertson SM, Davey RT, Voel J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008;24:591-9.
154. Roby CA, Dryer DA, Burstein AH. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001; 21:530-2.
155. Rock CL. Antioxidant supplement use in cancer survivors and the general population. In: Free radi-cals: the pros and cons of antioxidants. Bethesda, MD: National Institutes of Health, 2003.
156. Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF et al. Single plasma con-centrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam: midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol 2002;42:1079-82.
157. Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacoki-netics of indinavir. J Clin Pharmacol 2003;43:1283-8.
158. Schwarz UI, Büschel B, Kirch W. Unwanted preg-nancy on self-medication with St. John's wort de-spite hormonal contraception. Br J Clin Pharmacol 2003;55:112-3.
159. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
160. Shimomura S, Wanwimolruk S, Chen JJ. Drug in-teractions with grapefruit juice: an evidence-based overview. Pharmacy Times, March 2003, pp 87-95.
161. Smith GB, Harper PA, Wong JM, Lam MS, Reid KR, Petsikas D et al. Human lung microsomal cyto-chrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon re-ceptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2001;10:839-53.
162. Sood A, Sood R, Brinker FJ, Mann R, Loehrer LL, Wahner-Roedler DL. Potential for interactions be-tween dietary supplements and prescription medica-tions. Am J Med 2008;121:207-11.
163. Sridar C, Goosen T, Kent U, Williams J. Silybin inactivates cytochromes P450 3A4 and 2C9 and in-hibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-94.
164. Streetman DS, Bertino JS, Nafziger AN. Phenotyp-ing of drug-metabolizing enzymes in adults: a re-view of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10: 187-216.
165. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K et al. Different effects of St. John's wort on the pharmacokinetics of simva-statin and pravastatin. Clin Pharmacol Ther 2001; 70:518-24.
166. Sunter WH. Warfarin and garlic [letter]. Pharm J 1991;246:772.
167. Tattelman E. Health effects of garlic. Am Fam Phy-sician 2005;72:13-106.
168. Tomlinson B, Hu M, Lee VW. in vivoassessment of herb-drug interactions: possible utility of a pharma-cogenetic approach? Mol Nutr Food Res 2008; 52:799-809.
169. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbut-amide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46:1290-8.
170. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry drug interaction studies-study design, data analysis, implications for dosing, and labeling rec-ommendations (February 2012).
171. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM292362.pdf Accessed February 11, 2013.
172. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evi-dence. Ann Pharmacother 2000;34:1478-82.
173. van Erp NP, Baker SD, Zhao M, Rudek MA, Guche-laar HJ, Nortier JW et al. Effect of milk thistle (Si-lybum marianum) on the pharmacokinetics of iri-notecan. Clin Cancer Res 2005;11:7800-6.
174. van Strater AC, Bogers JP. Interaction of St. John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol 2012;27:121-4.
175. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediat-ed by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with en-zyme-inducing drugs. J Clin Pharmacol 1999;39: 567-77.
176. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphospho-glucuronosyl trans-ferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270-3.
177. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J et al. The influence of St. John's Wort on CYP2C19 activity with res-pect to genotype. J Clin Pharmacol 2004;44:577-81.
178. Wang XD, Li JL, Su QB, Guan S, Chen J, Du J et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St. John's wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol 2009;67:255-61.
179. Wang Z, Gorski JC, Hamman MA, Huang SM, Les-ko LJ, Hall SD. The effects of St. John's wort (Hy-pericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26.
180. Wargovich MJ. Experimental evidence for cancer preventive elements in foods. Cancer Lett 1997;114: 11-7.
181. Wargovich MJ, Woods C, Hollis DM, Zander ME. Herbals, cancer prevention and health. J Nutr 2001; 131:3034S-6S.
182. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
183. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-induci-ble cytochromes P-450 in the intestinal mu-cosa of rats and man. J Clin Invest 1987;80:1029-36.
184. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searlies PR et al. A crystal struc-ture of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003;42: 1430-8.
185. Weber HA, Zart MK, Hodges AE, Molloy HM, O'Brien BM, Moody LA et al. Chemical comparison of goldenseal (Hydrastis canadensis L.) root powder from three commercial suppliers. J Agric Food Chem 2003;51:7352-8.
186. Weisburger JH, Chung FL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol 2002;40:1145-54.
187. Wenk M, Todesco L, Krähenbühl S: Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyl-transferase 2, and xanthine oxi-dase in healthy males and females. Br J Clin Phar-macol 2004;57:495-9.
188. Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A. St. John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009;65:287-94.
189. Wittkowsky AK. Warfarin and other coumarin de-rivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-30.
190. Wrighton SA, Vandenbranden M, Stevens JC, Ship-ley LA, Ring BJ, Rettie AE et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug deve-lopment. Drug Metab Rev 1993;25: 453-84.
191. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of ber-berine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharma-cokinetic study. Eur J Clin Pharmacol 2005;61:567-72.
192. Xie R, Tan LH, Polasek EC, Hong C, TeillolFoo M, Gordi T et al. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005; 45:352-6.
193. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinet-ics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol 2006;28:25-9.
194. Yang CS, Chhabra SK, Hong JY, Smith TJ. Mecha-nisms of inhibition of chemical toxicity and carcino-genesis by diallyl sulfide (DAS) and related com-pounds from garlic. J Nutr 2001;131:S1041-5.
195. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004;44:538-42.
196. Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug inter-actions: experience with Ginkgo biloba and omepra-zole. Pharmacogenetics 2004;14:841-50.
197. Yoshida M, Katashima S, Ando J, Tanaka T, Uematsu F, Nakae D et al. Dietary indole-3-carbinol promotes endometrial adenocarcinoma development in rats initiated with N-ethyl-N'-nitro-N-nitroso-guanidine, with induction of cytochrome P450s in the liver and consequent modulation of estrogen metabolism. Carcinogenesis 2004;25:2257-64.
198. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nak-agawa M, Matsumoto T et al. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004;27:2006-9.
199. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients. Ann Intern Med 2004;141:23-7.
200. Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatté T et al. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 ac-tivity: a cocktail interaction study in healthy volun-teers. Eur J Clin Pharmacol 2012;68:553-60.
201. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Evidence for an involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 1997;43:245-52.
202. Zhang W, Han Y, Lim SL, Lim LY. Dietary regula-tion of P-gp function and expression. Expert Opin Drug Metab Toxicol 2009;5:789-801.
203. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
204. Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004;74:935-68.
205. Zhou SF. Drugs behave as substrates, inhi-bitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22.
206. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Phar-macokinet 2009;48:689-723.
207. Zhou SF, Wang B, Yang LP, Liu JP. Structure, func-tion, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268-354.
208. Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharma-cokinetics and pharmacokinetics of warfarin in rats. J Pharm Pharmacol 1999;51:175-80.
209. Zou L, Harkey MR, Henderson GL. Effects of herb-al components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71: 1579-89.
210. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 2010; 66:503-9.